Background/Aims: Pruritus, also known as itch, is a common, unpleasant sensation that can be difficult to treat. Frequently, chronic itch is associated with the development of neuropathic pain resulting from nerve injury or insult. Previous studies have shown the involvement of spinal microglia in the development of neuropathic pain, but their role in chronic pruritus is unclear. Methods: For this study, we constructed a model of chronic pruritus in mice using repeated applications of 2, 4-dinitrofluorobenzene (DNFB) and showed prolonged scratching behavior in treated mice that continued for at least 7 d after the final DNFB treatment. Results: Scratching was accompanied by activation of spinal microglia and both were reduced by an inhibitor of microglial activity. We also showed that microglial activation entailed increased signaling in the p38 MAPK pathway, and treatment with a p38 inhibitor reduced scratching in DNFBtreated mice. We also examined the role of fractalkine/CX3CR1 signaling in the development of DNFB-induced pruritus and showed that intrathecal administration of antiserum against either CX3CR1or FKN inhibited p38 activity and decreased scratching. Conclusion: Our results suggest that microglia are involved in pruritus induced by DNFB via FKN/CX3CR1/p38MAPK pathways similar to those participating in the development of neuropathic pain.
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Cellular Physiology and Biochemistry administration of FKN strongly induced p38 phosphorylation/activation in spinal microglial cells [33] . To our knowledge, FKN/CX3CR1 signaling has not been demonstrated in models of chronic pruritus. The goal of our research was to elucidate mechanisms involved in chronic pruritus using a previously-described mouse model of allergic dermatitis [36] . Repeated application of DNFB to nape skin produces dermatitis, elevated serum immunoglobulin E and provokes vigorous scratching behavior. Our results showed that activation of spinal cord microglia was involved in the development of pruritus utilizing the same FKN/CX3CR1/p38MAPK signaling pathways which also mediate the development of neuropathic pain.
Materials and Methods
Animals
Male adult ICR mice (25-35g) purchased from the Shanghai Laboratory Animal Center (Shanghai, China) were used. Experiments were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Animal care procedures were reviewed and approved by the Animal Study Committee at Jiaotong University School of Medicine, Shanghai, China. Animals were housed under a 12 h light/dark cycle in a pathogen-free area with free access to water and food.
Drugs and administration
To induce chronic pruritus, 150μl of 0.15% DNFB (Sigma-Aldrich, St. Louis, MO) in acetone was painted onto the shaved skin of the mouse nape for a total of four applications, twice in the first week and once per week for the next two weeks. Control mice received the same number of treatments, but were painted with acetone alone.
To study the effect of minocycline on pruritus induced by DNFB, 30mg/kg of minocycline (SigmaAldrich) was dissolved in sterile saline and administered via intrathecal injection 20min after the first DNFB painting, then once daily until the mice were sacrificed. The control groups received a vehicle (sterile saline for injection) according to the same schedule.
To study the role of p38, CX3CR1and FKN in the development of chronic pruritus, we performed blocking studies using the p38 inhibitor SB239063 (Sigma-Aldrich), the neutralizing antibody anti-mouse CX3CR1(Abcam, Cambridge, UK), and rabbit polyclonal anti-FKN (Abcam), respectively. Reagents were injected intrathecally 20min after the first DNFB painting, then once daily until the mice were sacrificed.
Behavioral analysis
Itch response evaluation was performed as described previously [37] . Hind paw scratching behaviors directed towards the painting site were recorded for 30 min starting at 2h, 3d and 7d after the last application of DNFB. For some experiments, the scratching behavior was recorded only on the third day following the last DNFB painting.
Immunohistochemistry
Mice were deeply anesthetized with 10% chloralhydrate and perfused through the ascending aorta with PBS followed by 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4). After the perfusion, the spinal cord and nape skin were removed and post-fixed in 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4) overnight. Samples were cut transversely into 30μm-thick frozen sections on a cryostat. Six section was collected as one set per animal and processed for immunofluorescence.
The following primary antibodies were used: goat polyclonal anti-Iba1 (1:500, Santa Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-phospho-p38 MAPK(1:500, Cell Signaling Technology, Danvers, MA), rabbit polyclonal anti-p38 MAPK(1:500, Cell Signaling Technology, Danvers, MA), rabbit polyclonal anti-CX3CR1 (1:1000, Abcam), and rabbit polyclonal anti-FKN (1:1000, Abcam). Sections were incubated with primary antibodies overnight at 4°C, and then with Alexa Fluor 488/594-conjugated species-specific secondary antibodies (1:1000; Invitrogen, Carlsbad, CA) for 1h at room temperature. In some experiments, double immunofluorescence staining was performed in which sections were incubated with a mixture of rabbit polyclonal and goat polyclonal primary antibodies, followed by a mixture of Alexa Fluor 488 and Alexa Fluor 594 secondary antibodies. 
Western blots
To examine the change in p-p38 protein expression, we performed western blots using spinal cord protein extracts from the experimental groups of mice. Cervical cord segments were dissected after behavioral tests and homogenized in T-PER Tissue Protein Extraction Reagent with 10% v/v Halt™ proteinase and phosphatase inhibitorcocktail (ThermoFisher Scientific, Waltham, MA). After centrifugation at 12000 rpm for 15 min at 4°C, the supernatant was collected, boiled with protein loading buffer at 100°C for 10 min and subjected to SDS-PAGE electrophoresis. Proteins were transferred to cellulose nitrate membranes. Blots were incubated with p38, p-p38 or CX3CR1 primary antibodies (1:1000 dilution for each) or mouse monoclonal anti-beta actin (1:5000, Abcam) overnight at 4°C, followed by horseradish peroxidase-conjugated secondary antibodyfor 1h at room temperature, then visualized with the Luminata™ Crescendo western HRP substrate (Millipore, Temecula, CA) .
Quantification and statistics
All data are presented as means ± SEM. Differences between groups were compared using Student's t-tests. P values <0.05 were considered significant.
Results
Microglia were activated 3 days after DNFB treatment DNFB treatment was previously established as a model of contact dermatitis [36] that has been utilized to produce acute itch [30, 38] and allergic pruritus [39] in mice. We recorded scratching behavior for 30 min at progressive time points following the cessation of DNFB treatment in mice receiving DNFB painting with and without intrathecal administration of the microglial inhibitor minocycline (Fig. 1A) . Scratching behavior was vigorous 2 h after the last DNFB treatment and, despite some subsidence in frequency, was still prevalent in DNFB-treated mice 7 d after the last painting, demonstrating the chronic nature of pruritus produced in this model. minocycline administration had no effect on scratching behavior 2 h after the final DNFB painting, but significantly reduced scratching by more than 50% 3 d after the last painting, compared to mice treated with DNFB alone. The effect of minocycline was no longer active 7 d after the last painting, when scratching was similar in both groups.
Since minocycline can inhibit microglial activation, we examined if intrathecal administration of minocycline affected microglial activation as shown by the microglialspecific marker Iba1 [23] . Results showed that microglial activation in the spinal cord increased 3 d after the cessation of DNFB treatment and that activation continued to a least the 7 d time point (Fig. 1B) . However, microglial activation did not occur until after the onset of scratching behavior, which was vigorous 2 h after the last DNFB painting. minocycline treatment reduced the number and intensity of Iba1-stained microglial cells at the 3 d time point, suggesting that reduced microglial activation was associated with diminished scratching at this time point.
p38 MAPK pathway in microglia was activated 3 days after DNFB treatment
To examine the possible involvement of the p38 MAPK pathway in the response of microglial cells to pruritogenic stimuli, we immunostained spinal cord sections for Iba1 and p-p38 expression 2 h, 3 d and 7d after the last DNFB treatment (Fig. 2A) . Separate groups of animals received intrathecal treatments with minocycline or the p38 inhibitor SB239063 during DNFB painting. Iba1 labeling in the spinal cord was increased 3 d and 7 d after the that the phosphorylation and activation of p38 is associated with the development of pruritus. Minocycline reduced activation of microglial cells as indicated by Iba1 staining, but SB239063 had little effect ( Fig. 2A) , suggesting that microglial activation promotes p38 phosphorylation but that p38 is not required for microglial activation. We also examined total and p-p38 levels by western blot (Fig. 2C) . The level of p-p38 protein in cervical spinal cord increased in animals receiving DNFB treatment, compared to control animals, while total p38 levels remained constant. Intrathecal administration of minocycline during DNFB treatment reduced p-p38 levels compared to mice that did not receive the drug, but p-p38 levels still exceeded those of control animals not painted with DNFB. In contrast, administration SB239063 resulted in a more extensive reduction in p-p38 expression 3 d after the end of DNFB treatment to levels seen in control non-painted mice. The decrease in p-p38 expression with SB239063 was associated with significantly diminished scratching behavior 3 d after cessation of DNFB treatment (Fig. 2D ), but scratching did not significantly differ between the treatment groups at the 7 d time point. These results suggest that p38 phosphorylation in activated spinal microglial cells is involved in the development of pruritus in response to DNFB treatment.
CX3CR1 expression in microglia was induced by DNFB treatment
We hypothesized that microglia may mediate the development of chronic pruritus via mechanisms similar to those regulating chronic pain, so we examined the role of FKN/ CX3CR1 signaling in our mouse model of chronic pruritus. Expression of the FKN receptor CX3CR1 was first analyzed by western blot in control animals receiving no treatment, in animals treated with DNFB alone, and in animals treated with DNFB and concomitantly
FKN/CX3CR1 signaling was involved in the activation of p38 and the development of chronic pruritus.
The increase in CX3CR1 expression following DNFB treatment suggested a role for FKN signaling in the development of chronic pruritus. To examine this putative signaling pathway, we administered daily intrathecal injections of a neutralizing antibody against the CX3CR1 receptor to block FKN signaling during DNFB painting, then assessed activation of the downstream p38 MAPK signaling pathway. Administration of the antibody reduced scratching behavior 3 d after the final DNFB treatment (Fig. 4A) and decreased the level of p-p38 in spinal cord homogenates as shown by western blot (Fig. 4B) . Total p38 expression was unchanged by DNFB or CX3CR1 antibody. The decrease in p-p38 expression by antibody administration is reflected in diminished p-p38 staining in cervical spinal cord sections by immunohistochemistry (Fig. 4C) . Quantitation of immunoreactive microglial cells showed a significant 50% reduction in p-p38-labeled cells in the spinal cords of animals treated with the antibody during DNFB painting compared to animals receiving DNFB treatment alone (Fig. 4D) . Similar results were obtained when a polyclonal FKN antibody was substituted for anti-CX3CR1 (Fig. 5) . Scratching behavior was reduced (Fig. 5A) , phosphorylation of p38 was inhibited (Fig. 5B) , and immunohistochemical visualization of p-p38 was diminished (Fig. 5C ) as was the number of p-p38-immunoreactive cells quantified per spinal section (Fig. 5D) . These results suggest that development of chronic pruritus in our DNFB model is mediated by FKN signaling through the CX3CR1 receptor and downstream activation of the p38 MAPK pathway.
Discussion
There is increasing evidence supporting a role for microglia in the pathogenesis of pain. Because pain and itch are closely related somatosensory sensations processed by secondorder neurons in the dorsal root ganglion [30] , microglial cells may act as neuroimmune regulators of both sensations [20] . In our study, we examined the potential role of microglia as mediators of chronic pruritus in a mouse model using repeated applications of DNFB to produce prolonged scratching for at least 7 d beyond the last pruritogenic application. Pruritus was associated with activation of spinal microglia monitored by increased expression of the microglial marker Iba1 and increased phosphorylation and activation of p38 MAPK. Intrathecal injections of microglial and p38 inhibitors during DNFB treatment reduced scratching and microglial activation. Chronic itch in our model was also associated with increased expression of the FKN receptor CX3CR1, and expression of CX3CR1 was inhibited by either microglial or p38 inhibitors. Activation of p38 was diminished by intrathecal injections of either anti-CX3CR1 or anti-FKN antibodies. We conclude that chronic pruritus in our model is mediated by spinal microglial activation via increased FKN signaling through the CX3CR1 receptor utilizing downstream p38 MAPK intracellular pathways.
It was interesting to note that increased scratching in our DNFB model occurred as early as 2 h after the final application of DNFB, whereas microglial activation, monitored by expression of Iba1, did not become apparent until 3 d after the final DNFB treatment. Scratching behavior at the 2 h time point may possibly reflect the response to acute pruritus mediated primarily by histamine-responsive neurons [8] . In contrast, chronic pruritus persisting after withdrawal of the pruritogenic stimulus may utilize mechanisms that activate microglia at a later time point. The failure of minocycline, which specifically inhibits microglial activation, to reduce scratching at the 2 h time point is a further indication that microglia may not mediate acute itch.
Despite the association of pain and pruritus, there are still differences in the pathways which mediate each sensation. For example, following spinal nerve ligation, Jin et al. reported that the level of p-p38 localized to spinal microglia increased after 0.5 d followed by delayed activation dorsal root ganglia neurons [26] . In contrast, in our model of chronic pruritus, we observed little change in p38 activation 2 h after the final DNFB painting, but expression of p-p38 was maximal 3 d later. Thus, downstream signaling may differ in neuropathic pain and involve earlier microglial p38 activation followed by later co-activation of p38 in both neurons and microglia.
The p38 enzymes represents a group of enzymes in the MAPK family that are phosphorylated and activated by a variety of physical and chemical stimuli [40] . In vitro studies have shown that activated p38 MAPK is present in spinal microglia and participates in signaling pathways that mediate nociception at the spinal cord level [41, 42] . However, the role of p38 in the development of chronic pruritus has not been elucidated. In our study, we examined total and phosphorylated p38 expression and showed increased levels of phosphorylated p38 by western blot 3 d and 7 d after the final treatment with DNFB, while total p38 remained constant. The number of microglial cells immunopositive for p-p38 in cervical spinal cord sections was increased at the same time points, validating our western blot results. The increase in p-p38 levels appears to be a later event in our pruritus model since there was no change in p-p38 expression 2 h after the last DNFB treatment when Iba1 levels had already increased and scratching behavior was maximal. Thus, mechanisms involved in the induction of scratching behavior differ from those involved in prolonged chronic scratching. Nonetheless, minocycline inhibition of microglial activation was associated with diminished p38 activation at the 3 d time point and administration of the p38 inhibitor SB239063 produced an even more profound reduction in p-p38, showing the specificity of p38-dependent signaling on inhibition of scratching behavior. Despite continual administration of SB239063 until the animals were sacrificed, scratching increased 7 d after the final DNFB painting and was no longer significantly different from scratching in animals receiving only DNFB treatment. This increase in scratching at 7 d also occurred in minocycline-treated mice and may reflect sensitization to the itch-inhibiting pathways with continued minocycline and SB239063 exposure. In future experiments, we intend to examine p38 expression and activation at 7 d and later time points to address this question.
The association of chronic pain and pruritus in adults has been demonstrated in epidemiological studies [11] and may indicate a common mediating mechanism. FKN signaling via the CX3CR1 receptor activates microglia in nerve injury [33] and could play a similar role in the development of chronic itch. We examined expression of CX3CR1 in our DNFB model of chronic pruritus and the effect of inhibitors of the FKN/CX3CR1 signaling pathway on scratching behavior and phosphorylation of p38. CX3CR1 expression increased on day 3 after the last application of DNFB in coordination with enhanced microglial activation indicated by Iba1 staining. Inhibition of microglia activation by minocycline or disruption of p38 signaling pathways by SB239063 both reduced receptor expression. 
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Intrathecal administration of antibodies against either CX3CR1 or FKN to disrupt signaling reduced p38 phosphorylation and suppressed scratching behavior. Thus, FKN/CX3CR1 signaling directly stimulated p38 activation in spinal microglia and may contribute to the development of chronic pruritus.
In conclusion, we have provided new evidence supporting a role for spinal microglial cells in the development of chronic pruritus in a mouse model induced by repeated applications of DNFB. The signaling pathways mediating pruritus appear similar to those implicated in the onset of neuropathic pain and likely involve FKN stimulation of CX3CR1 receptors leading to increased activation of the p38 MAPK pathway. We believe that future research focused on this pathway may lead to new clinical insights for improved treatment of chronic pruritus.
